Verona Pharma (VRNA) Competitors

Genmab A/S (NASDAQ:GMAB) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Which has stronger valuation and earnings, GMAB or VRNA?

Genmab A/S has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	5.76	$631.91M	$1.03	20.19
Verona Pharma	$460K	9,164.23	-$54.37M	-$1.92	-27.03

Do analysts rate GMAB or VRNA?

Genmab A/S presently has a consensus target price of $45.20, indicating a potential upside of 117.31%. Verona Pharma has a consensus target price of $50.57, indicating a potential downside of 2.54%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Which has more risk and volatility, GMAB or VRNA?

Genmab A/S has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Does the MarketBeat Community favor GMAB or VRNA?

Verona Pharma received 166 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 80.74% of users gave Verona Pharma an outperform vote while only 62.65% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%
Verona Pharma	Outperform Votes 327 80.74%	Underperform Votes 78 19.26%

Do institutionals & insiders have more ownership in GMAB or VRNA?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media favor GMAB or VRNA?

In the previous week, Verona Pharma had 1 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Verona Pharma and 7 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.96 beat Verona Pharma's score of 0.58 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verona Pharma	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GMAB or VRNA more profitable?

Genmab A/S has a net margin of 23.49% compared to Verona Pharma's net margin of 0.00%. Genmab A/S's return on equity of 14.64% beat Verona Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Verona Pharma	N/A	-79.54%	-43.49%

Summary

Genmab A/S beats Verona Pharma on 10 of the 19 factors compared between the two stocks.